CAR+ T Drug Development: The Critical Role Of Flow Cytometry

The rapid advancement of CAR+ T-cell therapies marks a significant milestone in the field of cellular immunotherapy, offering new hope for patients battling complex conditions like cancer. At the heart of this innovation lies flow cytometry, a critical technology that drives the success of CAR+ T-cell drug development.

This eBook provides an in-depth exploration of how flow cytometry has become essential for the characterization, monitoring, and validation of CAR-T cells in clinical trials. It covers the technological advancements that have standardized flow assays globally, enabling precise tracking of CAR-T cell expansion, persistence, and therapeutic efficacy. Addionally, readers will learn about the importance of flow cytometry in assessing minimal residual disease (MRD) and identifying biomarkers crucial for patient outcomes.

With contributions from leading experts at Cerba Research, this resource offers valuable insights into the challenges and solutions in CAR-T drug development. Access the eBook below for more insights into the intricate processes behind CAR-T therapies and the critical role of flow cytometry in advancing personalized medicine.